Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter
Purpose To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS). Materials and methods We retrospectively selected, in the 11 French centers, members of...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 2022-02, Vol.40 (2), p.489-495 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 495 |
|---|---|
| container_issue | 2 |
| container_start_page | 489 |
| container_title | World journal of urology |
| container_volume | 40 |
| creator | de Sallmard, Geoffroy Perrouin-Verbe, Marie-Aimée Peyronnet, Benoit Biardeau, Xavier Maucort-Boulch, Delphine Chartier-Kastler, Emmanuel Phé, Véronique Even, Alexia Joussain, Charles Dominique, Inès Amarenco, Gérard Gamé, Xavier Saussine, Christian Ruffion, Alain |
| description | Purpose
To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS).
Materials and methods
We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d’étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012).
Results
Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients.
Conclusions
IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications. |
| doi_str_mv | 10.1007/s00345-021-03850-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04151045v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638854678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-8458123e16f38da1ea1fb64ac2dcd2230aa336f1212f37c93c15d93bd57a72a73</originalsourceid><addsrcrecordid>eNp9kctuFDEURC0EIkPgB1ggS6xYNPjdPcsoCgRpJDawtm77wXjUYw-2e0h_Cz-LQ4ewY2XJdapuSYXQa0reU0L6D4UQLmRHGO0IHyTplidoQwXn3dAz9RRtSM9EJ7YDv0AvSjkQQntF5HN0wYViijG1Qb9uvA8GzIIhWlzAu7rg5HGINYN1Nc8lZTymOk8hzkdc012ITT04U0OKBfsmBxvSCeo-GJzOLkOTzg6PE1jrMi5LtDkdXXPhRgUXa8E_Q923kxhyDa1AgAnPOUTICy6nfYimuvwSPfMwFffq4b1E3z7efL2-7XZfPn2-vtp1RpBt7QYhB8q4o8rzwQJ1QP2oBBhmjWWMEwDOlaeMMs97s-WGSrvlo5U99Ax6fonerbl7mPQph2NroRMEfXu10_d_RFBJiZBn2ti3K3vK6cfsStWHNOfY6mmm-DBIofqhUWylTE6lZOcfYynR99vpdTvdttN_ttNLM715iJ7Ho7OPlr9jNYCvQGlS_O7yv9v_if0NPfGoeA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638854678</pqid></control><display><type>article</type><title>Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>de Sallmard, Geoffroy ; Perrouin-Verbe, Marie-Aimée ; Peyronnet, Benoit ; Biardeau, Xavier ; Maucort-Boulch, Delphine ; Chartier-Kastler, Emmanuel ; Phé, Véronique ; Even, Alexia ; Joussain, Charles ; Dominique, Inès ; Amarenco, Gérard ; Gamé, Xavier ; Saussine, Christian ; Ruffion, Alain</creator><creatorcontrib>de Sallmard, Geoffroy ; Perrouin-Verbe, Marie-Aimée ; Peyronnet, Benoit ; Biardeau, Xavier ; Maucort-Boulch, Delphine ; Chartier-Kastler, Emmanuel ; Phé, Véronique ; Even, Alexia ; Joussain, Charles ; Dominique, Inès ; Amarenco, Gérard ; Gamé, Xavier ; Saussine, Christian ; Ruffion, Alain</creatorcontrib><description>Purpose
To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS).
Materials and methods
We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d’étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012).
Results
Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients.
Conclusions
IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-021-03850-y</identifier><identifier>PMID: 34626226</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Balloon treatment ; Bladder ; Botulinum toxin ; Botulinum toxin type A ; Botulinum Toxins, Type A - adverse effects ; Female ; Humans ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Nephrology ; Neuromuscular Agents - adverse effects ; Oncology ; Original Article ; Patients ; Perineum ; Population studies ; Retrospective Studies ; Sphincter ; Treatment Outcome ; Urinary Bladder, Overactive - drug therapy ; Urinary Bladder, Overactive - etiology ; Urinary Sphincter, Artificial - adverse effects ; Urology</subject><ispartof>World journal of urology, 2022-02, Vol.40 (2), p.489-495</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-8458123e16f38da1ea1fb64ac2dcd2230aa336f1212f37c93c15d93bd57a72a73</citedby><cites>FETCH-LOGICAL-c409t-8458123e16f38da1ea1fb64ac2dcd2230aa336f1212f37c93c15d93bd57a72a73</cites><orcidid>0000-0001-5957-6811 ; 0000-0003-0042-7787 ; 0000-0003-0512-3459</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-021-03850-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-021-03850-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34626226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04151045$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>de Sallmard, Geoffroy</creatorcontrib><creatorcontrib>Perrouin-Verbe, Marie-Aimée</creatorcontrib><creatorcontrib>Peyronnet, Benoit</creatorcontrib><creatorcontrib>Biardeau, Xavier</creatorcontrib><creatorcontrib>Maucort-Boulch, Delphine</creatorcontrib><creatorcontrib>Chartier-Kastler, Emmanuel</creatorcontrib><creatorcontrib>Phé, Véronique</creatorcontrib><creatorcontrib>Even, Alexia</creatorcontrib><creatorcontrib>Joussain, Charles</creatorcontrib><creatorcontrib>Dominique, Inès</creatorcontrib><creatorcontrib>Amarenco, Gérard</creatorcontrib><creatorcontrib>Gamé, Xavier</creatorcontrib><creatorcontrib>Saussine, Christian</creatorcontrib><creatorcontrib>Ruffion, Alain</creatorcontrib><title>Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose
To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS).
Materials and methods
We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d’étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012).
Results
Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients.
Conclusions
IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications.</description><subject>Adult</subject><subject>Aged</subject><subject>Balloon treatment</subject><subject>Bladder</subject><subject>Botulinum toxin</subject><subject>Botulinum toxin type A</subject><subject>Botulinum Toxins, Type A - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Neuromuscular Agents - adverse effects</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Perineum</subject><subject>Population studies</subject><subject>Retrospective Studies</subject><subject>Sphincter</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urinary Bladder, Overactive - etiology</subject><subject>Urinary Sphincter, Artificial - adverse effects</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctuFDEURC0EIkPgB1ggS6xYNPjdPcsoCgRpJDawtm77wXjUYw-2e0h_Cz-LQ4ewY2XJdapuSYXQa0reU0L6D4UQLmRHGO0IHyTplidoQwXn3dAz9RRtSM9EJ7YDv0AvSjkQQntF5HN0wYViijG1Qb9uvA8GzIIhWlzAu7rg5HGINYN1Nc8lZTymOk8hzkdc012ITT04U0OKBfsmBxvSCeo-GJzOLkOTzg6PE1jrMi5LtDkdXXPhRgUXa8E_Q923kxhyDa1AgAnPOUTICy6nfYimuvwSPfMwFffq4b1E3z7efL2-7XZfPn2-vtp1RpBt7QYhB8q4o8rzwQJ1QP2oBBhmjWWMEwDOlaeMMs97s-WGSrvlo5U99Ax6fonerbl7mPQph2NroRMEfXu10_d_RFBJiZBn2ti3K3vK6cfsStWHNOfY6mmm-DBIofqhUWylTE6lZOcfYynR99vpdTvdttN_ttNLM715iJ7Ho7OPlr9jNYCvQGlS_O7yv9v_if0NPfGoeA</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>de Sallmard, Geoffroy</creator><creator>Perrouin-Verbe, Marie-Aimée</creator><creator>Peyronnet, Benoit</creator><creator>Biardeau, Xavier</creator><creator>Maucort-Boulch, Delphine</creator><creator>Chartier-Kastler, Emmanuel</creator><creator>Phé, Véronique</creator><creator>Even, Alexia</creator><creator>Joussain, Charles</creator><creator>Dominique, Inès</creator><creator>Amarenco, Gérard</creator><creator>Gamé, Xavier</creator><creator>Saussine, Christian</creator><creator>Ruffion, Alain</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-5957-6811</orcidid><orcidid>https://orcid.org/0000-0003-0042-7787</orcidid><orcidid>https://orcid.org/0000-0003-0512-3459</orcidid></search><sort><creationdate>20220201</creationdate><title>Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter</title><author>de Sallmard, Geoffroy ; Perrouin-Verbe, Marie-Aimée ; Peyronnet, Benoit ; Biardeau, Xavier ; Maucort-Boulch, Delphine ; Chartier-Kastler, Emmanuel ; Phé, Véronique ; Even, Alexia ; Joussain, Charles ; Dominique, Inès ; Amarenco, Gérard ; Gamé, Xavier ; Saussine, Christian ; Ruffion, Alain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-8458123e16f38da1ea1fb64ac2dcd2230aa336f1212f37c93c15d93bd57a72a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Balloon treatment</topic><topic>Bladder</topic><topic>Botulinum toxin</topic><topic>Botulinum toxin type A</topic><topic>Botulinum Toxins, Type A - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Neuromuscular Agents - adverse effects</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Perineum</topic><topic>Population studies</topic><topic>Retrospective Studies</topic><topic>Sphincter</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urinary Bladder, Overactive - etiology</topic><topic>Urinary Sphincter, Artificial - adverse effects</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Sallmard, Geoffroy</creatorcontrib><creatorcontrib>Perrouin-Verbe, Marie-Aimée</creatorcontrib><creatorcontrib>Peyronnet, Benoit</creatorcontrib><creatorcontrib>Biardeau, Xavier</creatorcontrib><creatorcontrib>Maucort-Boulch, Delphine</creatorcontrib><creatorcontrib>Chartier-Kastler, Emmanuel</creatorcontrib><creatorcontrib>Phé, Véronique</creatorcontrib><creatorcontrib>Even, Alexia</creatorcontrib><creatorcontrib>Joussain, Charles</creatorcontrib><creatorcontrib>Dominique, Inès</creatorcontrib><creatorcontrib>Amarenco, Gérard</creatorcontrib><creatorcontrib>Gamé, Xavier</creatorcontrib><creatorcontrib>Saussine, Christian</creatorcontrib><creatorcontrib>Ruffion, Alain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Sallmard, Geoffroy</au><au>Perrouin-Verbe, Marie-Aimée</au><au>Peyronnet, Benoit</au><au>Biardeau, Xavier</au><au>Maucort-Boulch, Delphine</au><au>Chartier-Kastler, Emmanuel</au><au>Phé, Véronique</au><au>Even, Alexia</au><au>Joussain, Charles</au><au>Dominique, Inès</au><au>Amarenco, Gérard</au><au>Gamé, Xavier</au><au>Saussine, Christian</au><au>Ruffion, Alain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>40</volume><issue>2</issue><spage>489</spage><epage>495</epage><pages>489-495</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose
To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS).
Materials and methods
We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d’étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012).
Results
Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients.
Conclusions
IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34626226</pmid><doi>10.1007/s00345-021-03850-y</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5957-6811</orcidid><orcidid>https://orcid.org/0000-0003-0042-7787</orcidid><orcidid>https://orcid.org/0000-0003-0512-3459</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 2022-02, Vol.40 (2), p.489-495 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04151045v1 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Balloon treatment Bladder Botulinum toxin Botulinum toxin type A Botulinum Toxins, Type A - adverse effects Female Humans Life Sciences Male Medicine Medicine & Public Health Nephrology Neuromuscular Agents - adverse effects Oncology Original Article Patients Perineum Population studies Retrospective Studies Sphincter Treatment Outcome Urinary Bladder, Overactive - drug therapy Urinary Bladder, Overactive - etiology Urinary Sphincter, Artificial - adverse effects Urology |
| title | Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20intradetrusor%20botulinum%20toxin%20injections%20for%20idiopathic%20overactive%20bladder%20syndrome%20in%20patients%20with%20an%20artificial%20urinary%20sphincter&rft.jtitle=World%20journal%20of%20urology&rft.au=de%20Sallmard,%20Geoffroy&rft.date=2022-02-01&rft.volume=40&rft.issue=2&rft.spage=489&rft.epage=495&rft.pages=489-495&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-021-03850-y&rft_dat=%3Cproquest_hal_p%3E2638854678%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638854678&rft_id=info:pmid/34626226&rfr_iscdi=true |